Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
NCT06682351
Not Yet Recruiting
The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatm... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2024
Locations: Stanford University, Stanford, California
Conditions: Prediabetes / Type 2 Diabetes
Register for Updates
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
NCT05073692
Recruiting
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Romain S. Neugebauer, Oakland, California +5 locations
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Register for Updates
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
NCT06046560
Completed
A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.
Gender:
ALL
Ages:
Between 27 years and 79 years
Trial Updated:
10/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Diseases, Diabetes
Register for Updates
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
NCT05577728
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Impact GLP-1 Agonists Following Bariatric
NCT06132477
Recruiting
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: University of Missouri Hospital, Columbia, Missouri
Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Register for Updates
GLP-1 and Hypoglycemia
NCT01858896
Active Not Recruiting
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
09/04/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
NCT04964388
Terminated
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
Gender:
FEMALE
Ages:
55 years and above
Trial Updated:
06/26/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland +7 locations
Conditions: Type2Diabetes, ASCVD
Register for Updates
Incretin Action in Physiology and Diabetes
NCT02550548
Completed
This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic intervention. However, there are important gaps in understanding incretin function that limit application of this system; this project will address several of these. A secondary, but critical aspect of this research is focus on inter-individual variation in the physiology of the in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/16/2023
Locations: Duke Center for Living, Durham, North Carolina
Conditions: Insulin Secretion
Register for Updates
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: HealthCore, Inc., Wilmington, Delaware +4 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
NCT01794143
Completed
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/13/2022
Locations: University of Alabama-Birmingham, Birmingham, Alabama +35 locations
Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Register for Updates
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551
Completed
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes. To evaluate safety, efficacy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400064, Birmingham, Alabama +123 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates